Takeda Pharmaceutical Co Ltd ADR (TAK) - Total Assets
Based on the latest financial reports, Takeda Pharmaceutical Co Ltd ADR (TAK) holds total assets worth $15.42 Trillion USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Takeda Pharmaceutical Co Ltd ADR - Total Assets Trend (2000–2025)
This chart illustrates how Takeda Pharmaceutical Co Ltd ADR's total assets have evolved over time, based on quarterly financial data. Also see TAK market cap for the company's overall valuation and market capitalisation.
Takeda Pharmaceutical Co Ltd ADR - Asset Composition Analysis
Current Asset Composition (March 2025)
Takeda Pharmaceutical Co Ltd ADR's total assets of $15.42 Trillion consist of 17.7% current assets and 82.3% non-current assets. Review TAK liabilities breakdown to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $233.74 Billion | 2.7% |
| Accounts Receivable | $725.25 Billion | 5.1% |
| Inventory | $1.22 Trillion | 8.5% |
| Property, Plant & Equipment | $1.97 Trillion | 13.8% |
| Intangible Assets | $3.63 Trillion | 25.5% |
| Goodwill | $5.32 Trillion | 37.4% |
Asset Composition Trend (2000–2025)
This chart illustrates how Takeda Pharmaceutical Co Ltd ADR's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See TAK stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Takeda Pharmaceutical Co Ltd ADR's current assets represent 17.7% of total assets in 2025, an increase from 0.0% in 2000.
- Cash Position: Cash and equivalents constituted 2.7% of total assets in 2025, up from 0.0% in 2000.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 62.0% of total assets, an increase from 0.0% in 2000.
- Asset Diversification: The largest asset category is goodwill at 37.4% of total assets.
Takeda Pharmaceutical Co Ltd ADR Competitors by Total Assets
Key competitors of Takeda Pharmaceutical Co Ltd ADR based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
GALDERMA GROUP AG
NYSE:GALDY
|
USA | $13.39 Billion |
|
Beijing Tongrentang Co Ltd
SHG:600085
|
China | CN¥31.82 Billion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥30.77 Billion |
|
Neuland Laboratories Limited
NSE:NEULANDLAB
|
India | Rs29.30 Billion |
|
China Resources Double-Crane Pharmaceutical Co Ltd
SHG:600062
|
China | CN¥17.01 Billion |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267
|
China | CN¥13.81 Billion |
Takeda Pharmaceutical Co Ltd ADR - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.19 | 1.31 | 1.53 |
| Quick Ratio | 0.65 | 0.72 | 1.10 |
| Cash Ratio | 0.25 | 0.24 | 0.00 |
| Working Capital | $506.60 Billion | $656.32 Billion | $939.72 Billion |
Takeda Pharmaceutical Co Ltd ADR - Advanced Valuation Insights
This section examines the relationship between Takeda Pharmaceutical Co Ltd ADR's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.08 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -5.7% |
| Total Assets | $14.25 Trillion |
| Market Capitalization | $52.60 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Takeda Pharmaceutical Co Ltd ADR's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Takeda Pharmaceutical Co Ltd ADR's assets decreased by 5.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Takeda Pharmaceutical Co Ltd ADR (2000–2025)
The table below shows the annual total assets of Takeda Pharmaceutical Co Ltd ADR from 2000 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | $14.25 Trillion | -5.70% |
| 2024-03-31 | $15.11 Trillion | +8.25% |
| 2023-03-31 | $13.96 Trillion | +5.92% |
| 2022-03-31 | $13.18 Trillion | +2.06% |
| 2021-03-31 | $12.91 Trillion | +0.71% |
| 2020-03-31 | $12.82 Trillion | -7.58% |
| 2019-03-31 | $13.87 Trillion | +237.82% |
| 2018-03-31 | $4.11 Trillion | -5.72% |
| 2017-03-31 | $4.36 Trillion | +13.90% |
| 2016-03-31 | $3.82 Trillion | -10.99% |
| 2015-03-31 | $4.30 Trillion | -5.97% |
| 2014-03-31 | $4.57 Trillion | +15.51% |
| 2013-03-31 | $3.96 Trillion | +10.58% |
| 2012-03-31 | $3.58 Trillion | +28.37% |
| 2011-03-31 | $2.79 Trillion | -1.31% |
| 2010-03-31 | $2.82 Trillion | +2.29% |
| 2009-03-31 | $2.76 Trillion | -3.13% |
| 2008-03-31 | $2.85 Trillion | -7.27% |
| 2007-03-31 | $3.07 Trillion | +0.99% |
| 2006-03-31 | $3.04 Trillion | +19.52% |
| 2005-03-31 | $2.55 Trillion | +8.98% |
| 2004-03-31 | $2.34 Trillion | +13.42% |
| 2003-03-31 | $2.06 Trillion | +4.79% |
| 2002-03-31 | $1.97 Trillion | +12.44% |
| 2001-03-31 | $1.75 Trillion | 0.00% |
| 2000-03-31 | $1.75 Trillion | -- |
About Takeda Pharmaceutical Co Ltd ADR
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Take… Read more